Clinical Trials Logo

Clinical Trial Summary

An open-label trial to explore the safety and efficacy of SM-020 gel 1.0% in subjects with Dermatosis Papulosa Nigra (DPN). Approximately 10 subjects will be enrolled with DPNs to apply SM-020 gel 1.0%. Each subject must have a minimum of 5 eligible DPNTLs with a diameter ≥2mm but ≤5mm. A maximum of 10 DPNs per subject will be targeted for treatment. Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study. A total of 5-10 eligible Dermatosis Papulosa Nigra Target Lesions (DPNTLs) will be treated per subject.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06099080
Study type Interventional
Source DermBiont, Inc.
Contact
Status Active, not recruiting
Phase Phase 2
Start date November 7, 2023
Completion date July 25, 2024

See also
  Status Clinical Trial Phase
Completed NCT03224598 - A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra Phase 2